Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Clinical-trials-phase-iii symbols : NVAX save search
Novavax Showcases Data from Expanding Vaccine Portfolio at IDWeek 2022
Published: 2022-10-20 (Crawled : 19:00) - biospace.com/
NVAX | $3.99 2.57% 2.51% 2.9M
|
Health Technology
|
| O: 0.39%
H: 2.44%
C: -4.56%
vaccine
Novavax Prototype COVID-19 Vaccine Data Support Homologous and Heterologous Boosting and Suggest Benefit Against Variants
Published: 2022-10-12 (Crawled : 13:00) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 1.29%
H: 0.0%
C: 0.0%
NVAX | $3.99 2.57% 2.51% 2.9M
|
Health Technology
|
| O: 1.27%
H: 5.93%
C: 5.36%
covid-19 vaccine prototype
Novavax Announces Extended Durability of Protection Against Infection and Disease in United Kingdom COVID-19 Vaccine Phase 3 Clinical Trial
Published: 2022-02-28 (Crawled : 23:00) - biospace.com/
NVAX | $3.99 2.57% 2.51% 2.9M
|
Health Technology
|
| O: -0.81%
H: 3.12%
C: 2.96%
covid-19 trial covid disease vaccine infection phase 3 infections
Novavax Announces Positive Results of COVID-19 Vaccine in Pediatric Population of PREVENT-19 Phase 3 Clinical Trial
Published: 2022-02-10 (Crawled : 00:00) - biospace.com/
NVAX | $3.99 2.57% 2.51% 2.9M
|
Health Technology
|
| O: -4.98%
H: 0.0%
C: 0.0%
covid-19 trial covid event-19 positive results positive vaccine phase 3
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.